secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001104659-23-101763
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants IDE approval for Orchestra BioMed's BACKBEAT pivotal study of BackBeat CNT in hypertensive pacemaker patients
--------------------------------------------------------------------------------

- FDA approved IDE for global pivotal BACKBEAT study evaluating AVIM therapy (BackBeat CNT) for hypertension in pacemaker patients.
- Study to randomize ~500 patients 1:1, primary endpoint: change in mean 24-hour ambulatory systolic BP at 3 months.
- Orchestra BioMed collaborating with Medtronic; Medtronic has exclusive global commercialization rights if approved.
- Supported by MODERATO II pilot study: net reduction of 8.1 mmHg in 24-hour aSBP and 12.3 mmHg in oSBP at 6 months.
- Enrollment expected to start before end of 2023; study designed to support future regulatory review and potential approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465923101763/0001104659-23-101763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465923101763/tm2326382d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-101763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer